Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

Unlike other breast cancer subtypes, patients with triple negative breast cancer (TNBC) have poor outcomes and no effective targeted therapies, leaving an unmet need for therapeutic targets. Efforts to profile these tumors have revealed the PI3K/AKT/mTOR pathway as a potential target. Activation of...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cells
Hlavní autoři: Wen, Wei, Marcinkowski, Emily, Luyimbazi, David, Luu, Thehang, Xing, Quanhua, Yan, Jin, Wang, Yujun, Wu, Jun, Guo, Yuming, Tully, Dylan, Han, Ernest S., Yost, Susan E., Yuan, Yuan, Yim, John H.
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770784/
https://ncbi.nlm.nih.gov/pubmed/31480338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8091010
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky